Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications

Lung cancer is the leading cause of cancer mortality. Despite therapeutic advances in recent years, new treatment strategies are needed to improve outcomes of lung cancer patients. Mutant p53 is prevalent in lung cancers and drives several hallmarks of cancer through a gain-of-function oncogenic pro...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Eziafa I. Oduah, Susan T. Sharfstein, Nagashree Seetharamu, Steven R. Grossman, Larisa Litovchick
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Frontiers Media S.A. 2024-04-01
Saila:	Frontiers in Oncology
Gaiak:	NSCLC proteasome TP53 mutant p53 proteasome inhibitor
Sarrera elektronikoa:	https://www.frontiersin.org/articles/10.3389/fonc.2024.1363543/full
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!